The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
GILD Buyback image

Gilead Sciences, Inc. Buyback

OLI recorded this information on 2/3/2015

Company: Gilead Sciences, Inc.
Buyback: GILD buyback
$Amount Authorized: $15,000,000,000
Buyback Details: The Board of Directors also approved the repurchase of up to an additional $15.0 billion of the company's common stock. This new program is in addition to the currently authorized three-year $5.0 billion repurchase program (authorized in May 2014). As of December 31, 2014, approximately $3 billion remained in the May 2014 program. The new program will expire 5 years after the completion of the May 2014 program. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Gilead's management and in accordance with the requirements of the Securities and Exchange Commission.

Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.

Gilead Sciences SEC Filing Email Alerts Service

Open the GILD Page at The Online Investor »

GILD — Key Stats (updated 13 hours, 20 minutes ago)
Company Name:  Gilead Sciences Inc
Stock buyback:  GILD buyback
Website:  www.gilead.com
Sector:  Biotechnology
Number of ETFs Holding GILD:  133
Total Market Value Held by ETFs:  $13.37B
Total Market Capitalization:  $84.40B
% of Market Cap. Held by ETFs:  15.84%
 

Open the GILD Page at The Online Investor (in a new window) »
April 17, 2024  •  11:50 PM Eastern
GILD — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree GILD Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Buy (2.83 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
GILD Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

GILD Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.